本研究主要是建立一個實驗轉移(experimental metastasis)的模型，來檢視IL-3 基因表現是否會影響腫瘤的轉移，因此我們比較我們評估鼠類自發性纖維瘤細胞(NFsa)及植入IL-3基因的纖維瘤(Nfsa-IL3)轉移到肺部的能力，以及分析由腫瘤引起的宿主免疫反應，並且檢視一氧化氮是否會影響腫瘤的轉移。在實驗的結果顯示，植入IL-3會降低腫瘤的轉移能力。雖然NFsa在後期，於肺部中會引起較多的的巨噬細胞浸潤其中，但此時的腫瘤會抑制其細胞毒殺的效果。另一方面，IL-3基因的表現會在腫瘤細胞還沒有抑制寄主免疫系統之前，即引起急性發炎反應(acute-phase inflammatory response)，後期寄主產生專一性T細胞(specific T cell)來攻擊剩下的腫瘤，並引起長效期免疫反應(long-term immunity)。這項研究也顯示NO在早期對植入IL-3基因的腫瘤轉移有影響，因為注射iNOS抑制劑，AG(aminoguanidine hemisulfate)於老鼠中，植入IL-3腫瘤會在肺部形成較多的肺群落。但由於注射AG，打入Nfsa-IL3的老鼠沒有死亡及產生長效期的腫瘤免疫反應，推測，NO不會影響腫瘤所產生的免疫反應(immunogenicity)。

The aim of this research was to establish an experimental metastatic model to study the influence of IL-3 on the process of metastasis. To this aim, we (1) compared the metastatic potential of a spontaneous murine sacroma, NFsa, and IL-3 gene-transfected tumor, Nfsa-IL3, to lung; (2) analyzed the immune responses induced by tumors; and (3) investigated the effects of NO on the processes of metastasis. The results show that the metastatic potential of NFsa was reduced by IL-3 gene transfection. Although the growth of NFsa tumors caused infiltration of macrophages, their cytotoxicity against tumors was inhibited by NFsa tumors. On the other hard, the expression of IL-3 could trigger acute-phase inflammatory responses prior to the development of tumor-associated inhibitory reaction. This dominant inflammatory reaction finally lead to the development of specific T cell response resulting in the final eradication of residual tumors and the development of long-term immunity. This study also shows that NO is only involved in the early process of a metastasis by the finding that the administration of iNOS inhibitor, AG, increased the number of NFsa-IL-3 lung colony. However, it did not affect the immunogenicity of NFsa-IL3 because these mice also developed long-term immunity.

1. Singh R.K. and Fidler I.J. : Regulation of tumor angiogenesis by organ-specific cytokines, In Attempts to understand metastasis formation II, Gunthert U. and Birchmeier W. (eds.), pp. 1-11 Spring-Verlag: Berlin Heidelberg, 1996
2. Powell W.C. and Matrisian L.M. : Complex roles of matrix metalloproteinases in tumor progression, In Attempts to understand metastasis formation I, Gunthert U. and Birchmeier W. (eds.), pp. 1-21 Spring-Verlag: Berlin Heidelberg, 1996
3. Easton E.W., Bolscher, Jan G. M. and Eijnden Dirk H. va den: Enzymatic amplification involving glycosyltransferase forms the basis for the increased size of asoaragine-linked glycans at the surface of NIH3T3 cells expressing the N-ras proto-oncogene. The Journal of biological chemistry, 226(32): 21674-21680, 1991
4. Raymond W. Ruddon: Biology of tumor metastasis, in Cancer Biology, pp.402-427, 3rd edition, Oxford University Press: U.S.A., 1995
5. Rozhin Jurij, Gomez Angel P., Ziegler Grace H, Neson Kevin K., Chang Yong Sook, Fong Dunne, Onoda James M., Honn Kenneth V., and Sloane Bonnie F.: Cathepsin B to cytesine protease inhibitor balance in metastaic cell subpopulations isoltaed from murine tumors. Cancer research, 50:6278-6287, 1990
6. Chauhan shyam S., Goldstein Lori J. and Gottesman Michael M.: Expression of cathepsin L in human tumors. Cancer research, 51:1478-1481, 1991
7. Richard E. B, Elisabeth A. Seftor, William G. Steler-Stevenson, and Mary J. C. Hendrix: The 72 kDa type IV collagenase is modulated cia differential expression of αVβ3 andα5β1 intergin during human melanoma cell invasion. Cancer research, 53:3411-3415, 1993
8. Anthony M. P. Montgomerym Yves A. De Clerch, Keith E. Langley, Ralph A. Reisfeld, and Barbara M. Mueller: Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase dependent and metalloproteinase-dependent proteolytic pathway. Cancer research, 53:693-700, 1993
9. Grondahl-Hansen J., Christensen I.J., Rosenquist C., Brummer N., Mouridsen H.T., Dano K., and Blichert-Toft M.: High levels of urokinase-type plasminogen activator and its inhibtor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor progenesis. Cancer research, 53:2513-2521, 1993
10.Liotta Lance A., Steeg Patrica S., and William G. Steler-Stevenson: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64:327-336, 1991
11.Imhof B.A., Gisler R.H. and Dunon D.: Involvement of α6 andαv integrins in metastasis. In Attempts to understand metastasis formation I, Gunthert U. and Birchmeier W. (eds.), pp. 195-203 Springer-Verlag:Brelin Heidelberg, 1996
Patel Poulam M., Flemming Claudia L., Russell Stephen J., Eccles Suzane A and Collins Mary K.L.: Cytokine gene transfer as therapeutic strategy. Journal of immunotherapy, 14:310-313, 1993
13.Hamblin Anne S.: Cytokines and cytokine receptors, Oxford University Press: U.S.A. 1993
14. Frendl, G. and Beller, D.I.: Regulation of macrophage activation by IL-3 I. IL-3 functions as a macrophage-activating factor with unique properties, incuding Ia and lymphocyte function-associated antigen-1 but not cytotoxicity. Journal of Immunology, 144:3392-3399, 1990
15.Frendl, G., Fenton, M. J. and Beller, D.I.: Regulation of macrophage activation by IL-3 II. Il-3 and lipopolysaccharide act synergistically in the regulation of IL-1 expression. Journal of Immunology, 144:3400-3410, 1990
16.Qin Z. and Blankestein T.: Influence of local cytokine on tumor metastasis:using ctyokine gene-transfected tumor cells. Attempts to understand metastasis formation III, Gunthert U. and Birchmeier W. (eds.), pp. 55-64, Springer-Verlag: Brelin Heidelberg, 1996
17.Rpsenberg Steven A., Spiess Paul, and Lafreniere Rene: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, Vol 233:1318-1321, 1986
18.Holling S.J., Darling D., GakenJ., Hirst W., Patel P., Kuiper M., Towner P., Humphreys S., Farzaneh F., and Mufti G.J. : Th effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. British Journal of Cancer, 74:6-15, 1996
19. Mcbride M. H., Dougherty G.D., Wallis A.E., Economou J. S., Chiang C. S.: Interleukin-3 in gene therapy of cancer. Folia Biologica, 40:62-73, 1994
20. Esandi MC, Someren GD van, Bout A, Mulder AH, Bekkum DW van, Valerio D and Noteboom JL: IL-1/IL-3 gene therapy of non-small cell lung cancer(NSCLC) in rats using ‘cracked’ adenoproducer cells. Gene therapy, 5:778-788
21. Pulaski Beth A., McAdam Alexander J, Elizabeth K. Hutter, Biggar Stephen, Lord Edith M. and Frelinger John G: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer research, 53:2112-2117, 1993
22.Pulaski BA, Yeh Kun-Yun, Shastri Nilabh, Maltby Kathleen M., Penny David P., Lord Edith M., and Frelinger John G.: Interleukin-3 enhances the cytotoxicity T lymphocyte development and class I major histocompability complex ‘representation’ of exogenous antigen by tumor-infiltrating antigen-presenting cells. PNAS, 93:3669-3674, 1996
Jenkins D. C., Charles I. G., Thomsen L.L., Moss D. W., Holmes L. S., Baylis S.A., Rhodes P., Westmore K., Meson P. C., and Moncada S.: Roles of nitric oxide in tumor growth. PNAS, Vol. 92:4392-4396, 1995
24. Xie Keping and Fidler Isaiah J.: Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer and metastasis review, 17:55-75, 1998
25. Wink David A., Vodovotz Yoram, Laval Jacques, Laval Francoise, Dewhirst Mark W. and Mitchell James B.: The multifacted roles of nitric oxide in cancer. carcinogenesis, 19:711-721, 1998
26. Brennan P.A., Downie I.P., Langdon J.D. and Zaki G.A.: Emerging role of nitric oxide in cancer. British Journal of Oral and Maxillofacial surgery, 37:370-373, 1999
27. Xie Keping and Fidler Isaiah J.: Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer and metastasis review, 17:55-75, 1998
28. Pipili-Synetos Eva, Sakkoula Eleni, Haralabopoulos G., Andriopoulou Paraskeiv, Peristeris P. and Maragoudakis M.E.: Evidence that nitric oxide is an endogenous antiangiogenic mediator. British Journal of Pharmacology, 111:894-902, 1994
29. Hobbs, M.V., Weigle W. O., Noonan, D.J., Torbett, B.E., McEvilly, R.J., Gurdenas, G.J. and Ernst, D.N.: Patterns of cytokine expression by CD4+ T cekks from yong and old mice. Journal of Immunology, 150:3602-3614, 1993
30. Kitagawa Masanobu, Kuwashima Toshio, Nemoto Tetsuo, Seki Sachiko, Matsubara Osamu and Kasuga Tsutomu: In vivo dynamic of pulmonary lymphoid cell subpopulations generated against pulmonary metastasis: evaluation by bronchoalveloar lavage fluid. Virchows Archiv B cell apthology, 58:365-370, 1990
31.Neeraj Jain, Kulpati D.D.S., Luthra Usha K., Gupta M.M. and Das D.K.: A study of bronchoalveolar larvage fluid (BALF) in the lung cancer. The Indian journal of chest diseases & allied sciences, Vol 30:103-110, 1988
32.Misko Thomas P., Morre William M, Kasten Thmoas P., Nickols G. Allen, Corbett John A., Tilton Ronald G., McDaniel Michael L., Williamson Joseph R. and Currie Mark G.: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. European Journal of Pharmacology, 233:119-125, 1993
33.巫緣昭：IL-3與一氧化氮對腫瘤生長的情形, 國立清華大學碩士論文，1998
34.Janeway Travers: ImmunoBiology, 3rd edition,Current Biology Ltd./Garland Publishing Inc.:U.S.A. 1997